In a turbulent market environment, VINC stock has reached its 52-week low, trading at $1.62, with technical indicators from InvestingPro showing the stock in oversold territory. This price level ...

The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.

Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...

Vincerx Pharma (VINC) announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which ...

SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through ...

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to ...

Vincerx Pharma announces early results for VIP943 and VIP236 in Phase 1 studies targeting hard-to-treat cancers, with complete responses seen in AML and HR-MDS patients and encouraging disease ...

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is ...